Eli Lilly (LLY) has secured Chinese regulatory approval for its oral GLP-1 weight-loss drug, orforglipron, becoming the first drugmaker to receive clearance for a GLP-1 weight-loss pill in the country, Reuters reported, citing China’s medicine regulator.
The approval gives Eli